SCHEMBL4347074

SCHEMBL4347074

CC(C)CN(C[C@H]1OC(C)(C)N(C(=O)O)[C@H]1Cc1ccc(OCc2cccc(C#N)c2)cc1)S(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.42
MMP13 P45452 4/20 0.42
MMP14 P50281 3/20 0.42
ADAMTS4 O75173 2/20 0.42
MMP2 P08253 1/20 0.42
ADAMTS5 Q9UNA0 1/20 0.42
FFAR1 O14842 2/20 0.38
FFAR4 Q5NUL3 1/20 0.38
ADAM17 P78536 3/20 0.36
RORC P51449 1/20 0.36
MMP1 P03956 1/20 0.36
KCNH2 Q12809 1/20 0.36
MLNR O43193 1/20 0.34
ABCB11 O95342 1/20 0.34
LMNA P02545 1/20 0.34
CTSD P07339 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP3A5 P20815 1/20 0.34
CNR1 P21554 1/20 0.34
TBXAS1 P24557 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13617758 0.85 ABCB1 (0.47) MAOBMMP13MMP14ADAMTS4MMP2
SCHEMBL4339792 0.83 TAS2R14 (0.38) MMP13MMP14ADAMTS4MMP2ADAMTS5
SCHEMBL4340869 0.82 LMNA (0.40) MAOBMMP13MMP14ADAMTS4MMP2
SCHEMBL4340851 0.82 MMP2 (0.49) MAOBMMP13MMP14ADAMTS4MMP2
SCHEMBL4347227 0.81 ADAMTS4 (0.46) MAOBMMP13MMP14ADAMTS4MMP2
SCHEMBL4353922 0.81 ADAM17 (0.37) MAOBMMP13MMP14ADAMTS4FFAR1
SCHEMBL4352479 0.81 MMP13 (0.40) MMP13MMP14ADAMTS4MMP2ADAMTS5
SCHEMBL4340203 0.80 MAOB (0.39) MAOBMMP13MMP14ADAMTS4MMP2
SCHEMBL4352169 0.79 MAOB (0.40) MAOBMMP13MMP14ADAMTS4MMP2
SCHEMBL4351904 0.79 BMP1 (0.44) MAOBMMP13MMP14ADAMTS4MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed
EP-1686113-A1 Inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2006-08-02 EP disclosed
EP-1194404-B1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2006-05-03 EP disclosed
US-6878728-B1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICAL INCORPORATED (US) 2005-04-12 US disclosed
US-20040122000-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED. 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122000-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 MAOB 4144/4885MMP13 900/4885MMP14 271/4885
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 MAOB 4144/4885MMP13 900/4885MMP14 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.